NCT05119920Phase 2Completed

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-07-27Actual

Enrollment · participants226Actual

Source updated2023-07-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Dry Eye Disease; Kerato Conjunctivitis Sicca

Treatments or interventions studied

Pilocarpine Ophthalmic Topical Cream, Dose 1DrugAlso known as GLK-301
Pilocarpine Ophthalmic Topical Cream, Dose 2DrugAlso known as GLK-301
Pilocarpine Ophthalmic Topical Cream, Dose 3DrugAlso known as GLK-301
Placebo Ophthalmic Topical CreamDrugAlso known as Placebo

Primary outcomes · main study measures

Read the study measures

measure: Mean change from baseline in the VAS score at Day 28 visit.; description: Mean change from baseline in the VAS score at Day 28 visit. Visual Analogue Scale from 0 (no discomfort) to 100 (maximal discomfort); timeFrame: Baseline and Day 28; measure: Mean change from baseline in Fluorescein Staining at the Day 28 visit.; description: Mean change from baseline in Fluorescein Staining at the Day 28 visit.; timeFrame: Baseline and Day 28

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history